menu
    • menu
    [{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Immunology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Immunology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Oncology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Oncology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Levomenthol","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NPB-06","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"NPF-08","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NPF-08","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NPO-13","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"NPO-13","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by NIHON PHARMACEUTICAL

    Menu

    NIHON PHARMACEUTICAL

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

                            Details : NPB-01 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Autoimmune Diseases of the Nervous System.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 05, 2022

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPO-13

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NPO-13 During Colonoscopy

                            Details : NPO-13 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intestinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 20, 2019

                            Lead Product(s) : NPO-13

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPF-08

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NPF-08 in Patients Who Receive Colonoscopy

                            Details : NPF-08 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 07, 2019

                            Lead Product(s) : NPF-08

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPF-08

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers

                            Details : NPF-08 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 06, 2018

                            Lead Product(s) : NPF-08

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levomenthol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

                            Details : NPO-11 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 28, 2017

                            Lead Product(s) : Levomenthol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPO-13

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase â…¡ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy

                            Details : NPO-13 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intestinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 16, 2014

                            Lead Product(s) : NPO-13

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPB-06

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis

                            Details : NPB-06 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 26, 2014

                            Lead Product(s) : NPB-06

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome

                            Details : NPB-01 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Guillain-Barre Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 20, 2014

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spe...

                            Details : NPB-01 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuromyelitis Optica.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 03, 2013

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NIHON PHARMACEUTICAL

                            Japan arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.

                            Details : NPB-01 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polyneuropathies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 09, 2013

                            Lead Product(s) : NPB-01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth